FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

Hospital

FibroGen

Michael D. Lowenstein

Elias Kouchakji

Richard Farley

R. Wayne Frost

Michael J. Martinelli

Pat Cotroneo

Leanne C. Price

Percy H. Carter

Christine L. Chung

Akshaya Patel Pharm.d.

Thane Wettig

Dr. Olga V. Gambetti M.D., Ph.D., Drmedsci

Lori S.

Aileen Huang (Cuihua)

Juan Graham

Simon Miller

Carol Gaddum

Claudia Witschi

Sarah Helgeson

Elena Vaisberg

Tricia Stewart

Dongxia Li

Kirk Christoffersen

Gerardo Pangilinan Ms, Dabt

Guangjie Guo

Gihani Wijewickrama

Jung Min Park

Krithica Sanjana

Zhao Hongda

Bernardo Lomongsod

Leadership Team

Clinical Development Team

Information Technology Team

Legal and Compliance Team

��

Teams at FibroGen

Leadership Team

Clinical Development Team

Information Technology Team

Legal and Compliance Team

��������

Teams at FibroGen

Leadership Team

Clinical Development Team

Information Technology Team

Legal and Compliance Team

��